- <![CDATA[New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons]]><![CDATA[Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.]]>onclive · 2mo ago↗ source
- Cytospire hauls in $83M for a new type of T cell engager<p>The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies. </p>BioPharma Dive · 2mo ago↗ source
- Celcuity strengthens case for ASCO-spotlighted breast cancer drug<figure><div><img src="https://imgproxy.divecdn.com/1TNhYQTUI7yObB637nFZIAJqv_C_vHe6B8CqUtpkWHg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTQwMTQ3MDc2LmpwZ…